.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX59_Enasidenib.Enasidenib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX59_Enasidenib.Enasidenib| name: | Enasidenib |
| ATC code: | L01XX59 | route: | oral |
| n-compartments | 2 |
Enasidenib is an oral, selective inhibitor of isocitrate dehydrogenase 2 (IDH2), used primarily in the treatment of relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. It is approved by the FDA and is currently used in clinical practice.
Pharmacokinetic parameters reported in adult patients (female and male) with relapsed or refractory AML following oral administration.
Li, Y, et al., & Zhou, S (2018). Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects. Pharmacology research & perspectives 6(6) e00436–None. DOI:10.1002/prp2.436 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30386625
Fan, B, et al., & Hossain, M (2022). Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia. Clinical pharmacology in drug development 11(4) 429–441. DOI:10.1002/cpdd.1067 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35166065